Canton Strategic Holdings (CNTN) Liabilities and Shareholders Equity (2020 - 2026)
Canton Strategic Holdings (CNTN) posted Liabilities and Shareholders Equity of $584.7 million for Q1 2026, up 12.62% on a QoQ basis from $519.1 million in Q4 2025, and up 35092.72% year-over-year from N/an in Q1 2025.
Canton Strategic Holdings (CNTN) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Canton Strategic Holdings' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $584.7 million for Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 35092.72% year-over-year to $584.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 5796.96% YoY) and the FY2025 annual result came in at $519.1 million, up 13849.46% from the prior year.
- Liabilities and Shareholders Equity was $584.7 million for Q1 2026 at Canton Strategic Holdings, up from $519.1 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $584.7 million in Q1 2026 and bottomed at $1.7 million in Q1 2025.
- A 5-year average of $70.7 million and a median of $7.7 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity tumbled 81.31% — and 2026, when it soared 35092.72%.
- Canton Strategic Holdings' Liabilities and Shareholders Equity stood at $6.7 million in 2022, then jumped by 63.66% to $10.9 million in 2023, then slumped by 66.0% to $3.7 million in 2024, then soared by 13849.46% to $519.1 million in 2025, then grew by 12.62% to $584.7 million in 2026.
- Business Quant data shows CNTN's Liabilities and Shareholders Equity at $584.7 million in Q1 2026, $519.1 million in Q4 2025, and $7.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Canton Strategic Holdings | 427.87 Mn | 427.87 Mn | - | 584.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 584.65 Mn |
| Dec 31, 2025 | 519.15 Mn |
| Sep 30, 2025 | 7.70 Mn |
| Jun 30, 2025 | 2.53 Mn |
| Mar 31, 2025 | 1.66 Mn |
| Dec 31, 2024 | 3.72 Mn |
| Sep 30, 2024 | 5.25 Mn |
| Jun 30, 2024 | 8.26 Mn |
| Mar 31, 2024 | 8.89 Mn |
| Dec 31, 2023 | 10.95 Mn |
| Sep 30, 2023 | 3.17 Mn |
| Jun 30, 2023 | 4.60 Mn |
| Mar 31, 2023 | 4.72 Mn |
| Dec 31, 2022 | 6.69 Mn |
| Sep 30, 2022 | 8.02 Mn |
| Jun 30, 2022 | 10.25 Mn |
| Mar 31, 2022 | 12.09 Mn |
| Dec 31, 2021 | 621,677.00 |
| Dec 31, 2020 | 294,798.00 |